pharma · Acute myeloid leukemia · Juvenile idiopathic arthritis
Istituto Gentili Italia
Istituto Gentili S.r.l.
Istituto Gentili S.r.l is a pharma organization headquartered in MILANO, IT. Primary therapeutic focus areas include Acute myeloid leukemia, Juvenile idiopathic arthritis, Malignant Pleural Mesothelioma, Osteogenesis Imp
Via San Giuseppe Cottolengo, 15, Milano, Lombardia 20143, IT HQ
1917 Founded
121 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Via San Giuseppe Cottolengo, 15, Milano, Lombardia 20143, IT
- Founded
- 1917
- Employees
- 121
- Programs
- 50
- Drugs
- 114
- Patents
- 0
Ultravist 370 mg/ml soluzione iniettabile
Phase 2 · small molecule · Patients with breast lesions undergoing further examination
Ultravist 370 mg/ml soluzione iniettabile for Patients with breast lesions undergoing further examination is a Phase 2 program (small_molecule) at Istituto Gentili S.r.l. with 1 ClinicalTrials.gov record(s).
Internal code IEO 960
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Istituto Gentili S.r.l.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Patients with breast lesions undergoing further examination
- Status
- active
- Trials
- 1